Matthew McKnight | Co-Founder & CEO
Perimeter Biosecurity

Matthew McKnight, Co-Founder & CEO, Perimeter Biosecurity

Matt McKnight is the Chief Executive Officer of Perimeter, the leading biosecurity infrastructure platform for national security. He began his career as an officer in the United States Marine Corps before supporting business development at Palantir Technologies. He subsequently spent seven years as an investor and served as President and COO at Decision Resources Group. Matt also serves as a General Partner at Four Cities Capital, a seed stage venture capital firm. Before founding Perimeter, Matt worked at Ginkgo Bioworks (NYSE: DNA) as head of its biosecurity business unit and as Chief Commercial Officer where he played a central role in scaling the company through its IPO in 2021. Matt holds a degree in History from Dartmouth College and is a graduate of the joint MBA/MPP program at Harvard Business School and the Harvard Kennedy School of Government, where he was a Zuckerman Fellow. He currently serves as a Fellow at the Belfer Center for Science and International Affairs at Harvard University, where he focuses on the intersection of biotechnology and national security.

Appearances:



Main Conference Day 1 - 9th March @ 17:30

Panel - Beyond PCR: Deploying Pathogen-Agnostic Sequencing and Next-Gen Sensing to Detect Engineered and Novel Threats

  • Moving Beyond Target-Specific Screening: Transitioning from traditional PCR assays toward continuous metagenomic sequencing and distributed, always-on sensing networks deployed across critical infrastructure, transit hubs, and healthcare settings.  
  • AI-Enabled Risk Characterization & Engineering Signatures: Utilizing frontier computational biology and AI to move beyond sequence identification—flagging deliberate genetic modifications, characterizing pathogen function, and predicting operational impact in real time.  
  • Funding & De-Risking Frontier Biodefense Tech: Strategies for catalytic capital, private sponsorship, and non-profit grant-making ($10M+ RFPs) to rapidly scale early-stage pathogen-agnostic hardware and software platforms.  
  • Translating Intelligence into Decisive Response: Bridging the gap between physical threat detection and operational action by establishing clear policy, government, and commercial response triggers before threats escalate.  
last published: 16/Nov/26 13:20 GMT

back to speakers